Related Experiment Videos

Taraxerol inhibits LPS-induced inflammatory responses through suppression of TAK1 and Akt activation

Xiangyang Yao1, Guilan Li, Qin Bai

  • 1Department of Biology and Food Engineering, Bengbu College, Bengbu, PR China. leeyxy@gmail.com

International Immunopharmacology
|January 22, 2013
PubMed

Insights

Taraxerol, a natural compound, reduces inflammation by inhibiting key signaling pathways like NF-κB. This study clarifies its molecular mechanisms, showing it blocks inflammatory mediator production in macrophages.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Immunology

Background:

  • Taraxerol is a triterpenoid with known anti-inflammatory properties.
  • The precise molecular mechanisms underlying taraxerol's anti-inflammatory effects remain unclear.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which taraxerol exerts its anti-inflammatory effects.
  • To investigate the impact of taraxerol on key inflammatory signaling pathways in macrophages.

Main Methods:

  • Assessing the effects of taraxerol on nitric-oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at protein and mRNA levels.
  • Analyzing the modulation of inflammatory mediators such as nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-1β.
  • Investigating the effects of taraxerol on the nuclear factor-κB (NF-κB) pathway, including IκBα phosphorylation and degradation, IKK, and MAPK activation.
  • Examining the role of TGF-β-activated kinase-1 (TAK1) and Akt signaling, including TAK1/TAK-binding protein1 (TAB1) complex formation and TAK1 ubiquitination and phosphorylation.

Main Results:

  • Taraxerol inhibited iNOS and COX-2 expression and decreased the production of NO, PGE2, TNF-α, IL-6, and IL-1β.
  • Taraxerol suppressed NF-κB translocation, IκBα phosphorylation, and degradation, while also inhibiting IKK and MAPK activation.
  • Taraxerol inactivated TAK1 and Akt signaling pathways, inhibited TAK1/TAB1 complex formation, and reduced TAK1 phosphorylation and polyubiquitination.

Conclusions:

  • Taraxerol effectively downregulates the expression of pro-inflammatory mediators in macrophages.
  • The anti-inflammatory action of taraxerol is mediated through the interference with TAK1 and Akt activation, consequently inhibiting NF-κB activation.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Formation of Lipopolysaccharides01:19

Formation of Lipopolysaccharides

Lipopolysaccharides (LPS) are crucial components of the outer membrane of Gram-negative bacteria, serving both structural and functional roles. It contributes to membrane stability and protects bacteria from host immune responses. LPS is composed of three major regions—lipid A, a core oligosaccharide, and an O antigen. The biosynthesis and assembly of LPS involve a highly coordinated set of enzymatic reactions and transport mechanisms. Additionally, LPS is recognized as an endotoxin, triggering...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...